Table 2. Outcomes of Interest.
| Outcome of interest | No. of studies, no. of patients | Statistical method, estimated effect, 95% CI | P value | I2 (%) |
|---|---|---|---|---|
| Duration of first hospitalization [15, 17, 23-27, 30, 34] | 9, 885 | MD: -0.48, 95% CI: -3.11 -2.16 | 0.72 | 98 |
| Overall duration of hospitalization [18, 21, 24-26, 28, 31, 33, 34] | 10, 605 | MD: -0.48, 95% CI: -2.86 -1.89 | 0.69 | 94 |
| Overall duration of hospitalization RCTs [28, 33, 34] | 3, 140 | MD: 1.48, 95% CI: -2.60 -5.57 (RE) MD: -0.94, 95% CI: -1.26 to -0.62 (FE) |
0.48 < 0.001 |
86 86 |
| Overall duration of hospitalization high-quality RCTs [33, 34] | 2, 100 | MD: -0.99, 95% CI: -1.31 to -0.67 (FE) | < 0.001 | 0 |
| Duration of IV antibiotics [22, 24, 25, 27, 34] | 5, 383 | MD: -0.52, 95% CI: -2.42 - 1.38 | 0.59 | 94 |
| Re-operations [14, 16, 20, 22, 34] | 5, 423 | Peto OR: 1.41, 95% CI: 0.64 - 3.13 | 0.40 | 81 |
| Overall complications [14-34] | 20, 1,660 | Peto OR: 2.90, 95% CI: 2.31 - 3.65 | < 0.001 | 78 |
| Abdominal/pelvic abscesses RCTs [33, 34] | 2, 100 | OR: 0.46, 95% CI: 0.17 - 1.29 | 0.14 | 0 |
| Abdominal/pelvic abscesses [14, 16, 17, 23, 26, 30, 31, 32-34] | 11, 1,116 | OR: 3.13, 95% CI: 1.18 - 8.30 | 0.02 | 71 |
| Wound infections [16, 17, 19, 20, 22, 23, 26-28, 30, 32] | 12, 1,094 | OR: 3.95, 95% CI: 1.95 - 8.00 | < 0.001 | 43 |
RCTs: randomized controlled trials; IV: intravenous; MD: mean difference; RE: random-effects; FE: fixed-effects; OR: odds ratio.